References
- Ouchi Y. Imaging neuroinflammation to monitor α-synucleinopathy. Lancet Neurol. 2017;16(10):763–764.
- Ghadery C, Koshimori Y, Christopher L, et al. The interaction between neuroinflammation and β-amyloid in cognitive decline in Parkinson’s disease. Mol Neurobiol. 2020;57(1):492–501.
- Liu Z, Qiu AW, Huang Y, et al. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson’s disease. Brain Behav Immun. 2019;81:630–645.
- Stokholm MG, Iranzo A, Østergaard K, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 2017. 2017;16(10):789–796.
- McGeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38(8):1285–1291.
- Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006;21(2):404–412.
- Lawson LJ, Perry VH, Dri P, et al. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990;39(1):151–170.
- Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35.
- Wenz T. Mitochondria and PGC-1α in aging and age-associated diseases. J Aging Res. 2011;2011:810619.
- Navarro E, Gonzalez-Lafuente L, Pérez-Liébana I, et al. Heme-oxygenase I and PCG-1α regulate mitochondrial biogenesis via microglial activation of Alpha7 nicotinic acetylcholine receptors using PNU282987. Antioxid Redox Signal. 2017;27(2):93–105.
- Yang X, Xu S, Qian Y, et al. Resveratrol regulates microglia M1/M2 polarization via PGC-1α in conditions of neuroinflammatory injury. Brain Behav Immun. 2017;64:162–172.
- Ma L, Niu W, Lv J, et al. PGC-1α-mediated mitochondrial biogenesis is involved in cannabinoid receptor 2 agonist AM1241-induced microglial phenotype amelioration. Cell Mol Neurobiol. 2018;38(8):1529–1537.
- Wang Y, Ruan W, Mi J, et al. Balasubramide derivative 3C modulates microglia activation via CaMKKβ-dependent AMPK/PGC-1α pathway in neuroinflammatory conditions. Brain Behav Immun. 2018;67:101–117.
- Wang Y, Zhao W, Li G, et al. Neuroprotective effect and mechanism of thiazolidinedione on dopaminergic neurons in vivo and in vitro in Parkinson’s disease. PPAR Res. 2017;2017:4089214.
- Katsouri L, Lim YM, Blondrath K, et al. PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer’s disease model. Proc Natl Acad Sci USA. 2016;113(43):12292–12297.
- Zhang Y, Chen C, Jiang Y, et al. PPARγ coactivator-1α (PGC-1α) protects neuroblastoma cells against amyloid-beta (Aβ) induced cell death and neuroinflammation via NF-κB pathway. BMC Neurosci. 2017;18(1):69.
- Kim SJ, Park C, Lee JN, et al. Protective roles of fenofibrate against cisplatin-induced ototoxicity by the rescue of peroxisomal and mitochondrial dysfunction. Toxicol Appl Pharmacol. 2018;353:43–54.
- Fu X, Qin T, Yu J, et al. Formononetin ameliorates cognitive disorder via PGC-1α pathway in neuroinflammation conditions in high-fat diet-induced mice. CNS Neurol Disord Drug Targets. 2019;18(7):566–577.
- Molteni M, Rossetti C. Neurodegenerative diseases: the immunological perspective. J Neuroimmunol. 2017;313:109–115.
- Ghasemi F, Bagheri H, Barreto GE, et al. Effects of curcumin on microglial cells. Neurotox Res. 2019;36(1):12–26.
- Jin X, Liu MY, Zhang DF, et al. Natural products as a potential modulator of microglial polarization in neurodegenerative diseases. Pharmacol Res. 2019;145:104253.
- Labzin LI, Heneka MT, Latz E. Innate immunity and neurodegeneration. Annu Rev Med. 2018;69:437–449.
- Franco-Bocanegra DK, McAuley C, Nicoll J, et al. Molecular mechanisms of microglial motility: changes in ageing and Alzheimer’s disease. Cells. 2019;8(6):639.
- Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–964.
- Chawla A. Control of macrophage activation and function by PPARs. Circ Res. 2010;106(10):1559–1569.
- St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127(2):397–408.
- Zheng B, Liao Z, Locascio JJ, et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med. 2010;2(52):52ra73.
- Mudò G, Mäkelä J, Di Liberto V, et al. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell Mol Life Sci. 2012;69(7):1153–1165.
- Jiang H, Kang SU, Zhang S, et al. Adult conditional knockout of PGC-1α leads to loss of dopamine neurons. eNeuro. 2016;3(4):ENEURO.0183-16.2016.
- Nijland PG, Witte ME, van Het Hof B, et al. Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: implications for multiple sclerosis. Acta Neuropathol Commun. 2014;2:170.
- Su X, Chu Y, Kordower JH, et al. PGC-1α promoter methylation in Parkinson’s disease. PLoS One. 2015;10(8):e0134087.
- Dölle C, Flønes I, Nido GS, et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nat Commun. 2016;7:13548.
- Kustrimovic N, Marino F, Cosentino M. Peripheral immunity, immunoaging and neuroinflammation in Parkinson’s disease. Curr Med Chem. 2019;26(20):3719–3753.